

**Study #:** POM-003

**EudraCT#:** 2017-004370-34

**Title of Study:** A Prospective Study in Subjects with Late-onset Pompe Disease who are Currently Being Treated with Enzyme Replacement Therapy

Due to the regulatory authorities' recommendations for a different design of the Phase 3 program, Study POM-003 was closed so that subjects could enroll directly into the double-blind, randomized Study ATB200-03, whether or not they had previously participated in Study POM-003. The longest treatment duration was approximately 7 months in this study. No significant AEs or SAEs were noted during treatment with alglucosidase alfa.